Cohort Descriptives

Variable Response
Cohort Name MEMENTO: a cohort of outpatients from French research memory centers in order to improve knowledge on Alzheimer’s disease and related disorders
Cohort Acronym MEMENTO
Study Overview DESIGN OF THE STUDY A Multicenter national prospective cohort study including at least 2300 individuals consecutively recruited from French memory clinics (CMRRs) and followed-up over 5 years. A pilot phase has been run in 5 memory clinics that have volunteered for that phase and were eligible for the cohort (Bordeaux, Lille, Marseille, Paris Pitié-Salpêtrière, Toulouse). Eligible memory clinics are those that may include at least 50 individuals during the inclusion period, have access to MRI (1.5 or 3T) and biobank facilities. PRIMARY OBJECTIVE To study the evolution of a variety of potentially early preclinical signs of AD and related disorders and to estimate the prognostic value of several markers (neuropsychological, vascular damage indicators, psycho-behavioral, socio-economic, genetic, blood, neuroimaging) on progression from early signs to clinical dementia or severe cognitive deterioration stages, and then to death. SECONDARY OBJECTIVES * To assess the validity of an operational set of criteria to help identifing the transition from pre-clinical dementia stages, * To study how vascular risk factors or damage markers are associated with the risk of progression to clinical dementia stage, * To study prevalence and incidence of prodromal AD or symptomatic pre-dementia according to different definitions, * To assess factors explaining the variability in time of clinical diagnosis of ADRD, * To study the relationships between neuropsychiatric symptoms and Alzheimer’s disease or associated dementia progression, * To assess factors predicting: Mortality, Loss of autonomy, Institutionalisation, Rate of cognitive decline in different areas of cognition, Cardiovascular events during follow-up, Change in quality of life, Risk of developing prodromal AD (pre-symptomatic dementia) * To study factors associated with change in biomarkers * To study the frequency of Lewy Body Disease (LBD) symptoms at an early stage and to compare MCI-AD and MCI-LBD participants in term of clinical symptoms, cognition, cerebral imaging characteristics and outcomes * In the subsample of participants who will reach the clinical stage of dementia, specific objectives will consist in: -assessing the evolution of the social, behavioural and quality of life characteristics of the participants and their caregivers over time and their relation with clinical progression of the disease; -describing the efficiency of resources that are used over time GUIDING PRINCIPLES OF THE COHORT This cohort, solution to the item 29 of the Plan Alzheimer 2008-2012, has been developed according to the initial memorandum of understanding prepared by the "Comité Plan Cohortes" of the Fondation Plan Alzheimer, and taking on board comments provided by the Scientific Advisory Board (July 2010) of the Fondation Plan Alzheimer and the whole working groups constituted for the preparation of the pilot phase: clinicians, neuro-imaging specialists, biologists, social sciences researchers (from June 2010). The cohort is built to fulfil the guiding principles as follows: * It should be scientifically original and identify hypothesis-driven research, allowing a corpus of new or confirmatory knowledge of a high-level of evidence to be acquired. In addition, the infrastructure (standardised collection of socio-demographic, clinical, imaging, biological data) may allow to respond, in a timely manner, to additional questions that may emerge over time; * An interdisciplinary approach is set up as the condition of individuals affected by neurodegenerative dementias involves clinical and biological aspects but also environmental, social and economic components; * While pursuing its own original scientific objectives, the cohort should have the potential for a comparison with other equivalent cohorts around the world. This cohort will be including individuals at high risk of developing a neurodegenerative dementia. As such, the cohort is aiming at providing results with an expected impact for those individuals of the same profile, as well as their caregivers and their case management
#Subjects at Baseline 2323
Institution Name Bordeaux University Hospital
Department Name Center for Clinicial Investigation (CIC 1401), Clinical Epidemiology
City Bordeaux
Study/Database Website

Principal Investigator (PI) Carole Dufouil
Key Study References

Cognitive and imaging markers in non-demented subjects attending a memory clinic: study design and baseline findings of the MEMENTO cohort. Dufouil et al. Alzheimers Res Ther 2017

Population Based Study? No
Family Based Study? No
Clinical based sample? Yes
Is there follow-up data available? Yes
Were participants included prior to development of dementia (may refer to controls only)? Yes (all)
Were participants included prior to development of MCI (may refer to controls only)? Yes (subsample)
How is data collected? Through a dedicated electronic CRF website
Who carries out data collection? Clinical sites CRA
Does this take place in participants' homes or at a central location? Central location (at clinical site)
Do participants take part individually or are families/partners involved? Individualy. An informant might be involved to complete questionnaires, and a dedicated Informant questionnaire is available (optional)
Dementia cases ascertained as part of study: Yes
Diagnosis based on review of existing clinical data Yes
Was diagnosis/primary outcomes made blind to exposure variables? Yes
How many times followed up? 11 (Inclusion and 5 annual visits on site, 5 intermediate visits on site or by phone)
Study start date January 2011
Is study ongoing? Yes
Is study still recruiting? No
Inclusion criteria *Aged 18 years and above *Having at least a light cognitive deficit defined as performing worse than one standard deviation to the mean (compared to age and educational norms) in one or more cognitive domains (assessed from a neuropsychological tests battery exploring memory, language, praxis, vision, executive functions); this deviation being identified for the first time by tests performed less than 6 months preceding date of inclusion (i.e. signature of informed consent) Or *Having isolated cognitive complaint regardless of its duration while being 60 years and older (i.e. without cognitive deficit as defined above)(maximum stratum size of 300 participants) ; *Clinical Dementia Rating scale <=0.5 and not demented *Visual and auditory acuity adequate for neuropsychological testing *Having signed an informed consent *Being affiliated to health insurance
Exclusion criteria * Being under guardianship * Residence in skilled nursing facility * Pregnant or breast feeding women * Alzheimer's disease caused by gene mutations * Meeting brain MRI exclusion criteria (pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin, or body) or refusing MRI * Having a history of intracranial surgery * Having a neurological disease such as: treated epilepsy, treated Parkinson's disease, Huntington disease, brain tumour, subdural haematoma, progressive supranuclear palsy, history of head trauma followed by persistent neurological deficits * Stroke that has occurred in the last three months * Schizophrenia history (DSM-IV criteria) * Illiteracy, is unable to count or to read


Variable type Variables generally collected
Anonymised subject and Center IDs Y
Date and country of birth Y
Data of consent Y


Variable type Variables generally collected
Age at inclusion Y
Education Y
Occupation history Y
Household income Y
Accommodation Y
Marital status Y
Spouse occupational history Y
Native language Y

Family History

Variable type Variables generally collected
History of dementia Y
History of epilepsy Y
History of stroke Y
History of language trouble Y
History of Parkinson's Y
History of paraplegia Y
History of myopathy Y

Physical Health Status

Variable type Variables generally collected
Physical evaluation Y
Neurological evaluation Y
Parkinson's disease signs, tremor Y
Comprehensive medical history (any disease, any location, any time) Y
Medical history prior to clinical site attendance Y
Eye disease Y
Handedness Y
Hearing aid Y
Treatments at inclusion and onwards Y
Medical events since inclusion Y

Reproductive History

Variable type Variables generally collected
Menopausal status Y
Hormone replacement therapy Y

Health Care Utilisation

Variable type Variables generally collected
Help at home (cleaning, nursing, meals) Y
Day-care centre use Y
Personal Autonomy Allowance Y
Long term condition exemption Y
Medical and paramedical follow-up Y
Insurance Y

Life Functionality

Variable type Variables generally collected
Instrumental Activities of Daily Living (IADL) Y
Activities of Daily Living (ADL) Y

Mental Health Status

Variable type Variables generally collected
Neuropsychiatric inventory (NPI) in 12 domains: Delusions, Hallucinations, Agitation, Depression, Anxiety, Euphoria, Apathy, Disinhibition, Irritability, Motor disturbance, Sleep disorders, Appetite Y
Subjective difficulties Y
Quality of life (EuroQol EQ-5D) Y

Cognitive Status

Variable type Variables generally collected
Clinical Dementia Rating (CDR) scale Y
Dementia (At each visit on site, dementia was stated by the clinician: date and etiology. Diagnostic was based on DSM-IV-TR and NINCDS-ADRDA criteria. All cases were reviewed by an Endpoint Committee Review, blinded of PET, genetic and CSF data. If dementia: Hachinski score, Lebert and Pasquier's fronto-temporal behavioural scale and McKeith criteria. Y


Variable type Variables generally collected
Tobacco use Y
Alcohol consumption Y
Mini-Nutritional Assessment (MNA) Y
Leisure Y

Social Environment

Variable type Variables generally collected
Occurrence and impact of life events (Stress Response Rating Scale) Y
Social Network Y
Relatives connection Y
Informant self-assessment questionnaire (including CES-D, Zarit and Stress scale) Y
Informant Quality of life Questionnaire (LEIPAD) Y

Physical Examination

Variable type Variables generally collected
Anthropometric measures Y
Blood pressure Y
Neurological examination Y
Evaluation of Parkinson's syndrome Y
Evaluation of Lewy Body disease signs Y
International Performance Assessment Questionnaire Y
Short Physical Performance Battery Y

Biosample Assays

Variable type Variables generally collected
Blood Biochemistry Y
Haematology Y
Serology if relevant (HBV, HCV, HIV, Syphilis) Y
CSF (subsample) Y

Digital Phenotyping

Variable type Variables generally collected
Comprehensive Neuropsychological tests battery: At each annual visit on site, and at intermediate visit if CDR>=1: - Delay Matching Sample 48 (DMS48) immediate and at 60' - Free and Cued Selective Reminding Test immediate and 20' - Frontal Assessment Battery - Praxis - Verbal fluencies 2' (Letter P, Animals) - Trail Making Test (TMT) A and B - Rey figure copy and 3' (optional: 30') - Digit Span (optional: Visuo-spatial span) - Naming Object 80 Y
Subjective complaints: physical, attention, memory, language, mood, general state of health, stress, sensory organs Y


Variable type Variables generally collected
Brain MRI 3D-T1 Y
Brain MRI 2D-T2* Y
Brain MRI Resting State Y
Brain MRI Diffusion Y
18-FDG PET (subsample) Y
Amyloid PET (subsample) Y


Variable type